|Marianne Alanko Blomé, MD, Ph.D, is working as a clinician at the Dept. of Infectious Diseases at the Skåne University Hospital in Malmö and as a medical officer at the regional office for communicable disease control in Skåne. She is the
medical supervisor of the Malmö Needle Exchange Program. She is engaged in virological and epidemiological research on transmission of bloodborne viruses among people who inject drugs, with the main focus on HCV.
|Niklas Björkström is a resident physician in clinical microbiology at Karolinska University hospital, Huddinge, Sweden, and an Associate Professor in Immunology. He leads a research team within Center for Infectious Medicine at ANA Futura - a newly built research facility at Karolinska Institutet. The main focus of the research group is to understand more about the biology behind tissue-resident natural killer (NK) cells. The previous hypothesis that NK cells mainly recirculate from tissue to blood has been re-evaluated in recent years, and it is now known that NK cells are much more tissue-specific than what was earlier believed. One part of the groups research is to gain better insight into the function and course of development of uterine resident NK cells, by detailed characteriztion of their cell surface expression of killer immunoglobulin-like receptors (KIR). Another interest of the group is resident NK cells in the liver. The goal is to understand how these cells might be involved in the pathogenesis of different liver diseases, such as primary sclerosing cholangitis (PSC), steatohepatitis (NASH), and hepatitis virus infections (HBV, HCV, HDV), all inflammatory conditions associated with an increased risk of tumor development. The group is specialized in advanced 30-parameter flow cytometry and microscopy, and use these techniques for phenotypic and functional studies of NK cells in health and disease. Recently they have also developed a sensitive method for isolating and analyzing immune cells from the bile duct tree, which so far is a relatively unexplored organ from an immunological point of view.|
|Maria Buti earned her medical degree at the University of Barcelona and her PhD in Internal Medicine at the University “Autónoma” de Barcelona, Spain. She is currently Professor of Medicine and Chief of Internal Medicine and Hepatology at the Hospital General Universitari Valle Hebron, Barcelona. Dr Butí has worked in viral hepatitis for the 30 years, particularly in diagnosis and therapy of hepatitis B and C. She has been published widely more than 400 manuscripts in peer review journals in the field of viral hepatitis and contributions to books. She is in the Editorial Board of Journal of Hepatology and Liver International. She is part of the expert Committee in the Spanish National Plan against Hepatitis C. She is very active in clinical trials and has been principal investigator in many studies.
She was president of the Spanish Association for the Study of Liver Diseases, and an active member of the EASL, and the AASLD and various professional societies.
|Christina Carlander is a senior consultant of Infectious Diseases at Västmanland County Hospital, Västerås.
She is a senior researcher at the Dep. of Medicine, Huddinge, Karolinska Institutet and also affiliated to the Dep. of Medical Epidemiology and Biostatistics, Karolinska Institutet and to the Centre of Clinical Research, Västmanland County Hospital.
Christina’s research is focused on registry-based epidemiological studies of the Swedish HIV cohort. In her thesis she studied incidence and risk of HPV-related cervical cancer and precancer in women living with HIV in Sweden, with particular focus on migrants. Her present studies continues in the field of HPV related cancer in people living with HIV but also involves other HIV/cancer-comorbidity as well as studies in the field of social medicine such as connection to the labor market depending on HIV status.
|Claudia Crowell, MD, MPH is Associate Professor of Pediatric Infectious Diseases at the University of Washington in Seattle, Washington. Her research has focused on Pediatric HIV treatment and complications. She has been a site co-investigator for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) network and is currently a member of the U.S.–based multi-site Pediatric HIV/AIDS Cohort Study (PHACS). Most recently she has been leading studies of effects of in utero antiretroviral drug exposure in HIV-exposed uninfected children within the PHACS.|
|Olav Dalgard is a professor of infectious diseases at Akershus University Hospital in Norway. His main research interest is hepatitis C infection in people who inject drugs focusing on natural history of the disease and delivery of care. He is currently studying new models of care for HCV among PWID and reinfection after successful HCV treatment. He has been chairing the committee who writes HCV and HBV treatment guidelines in Norway and is a member of the work group writing HCV guidelines for the European Association for the study of Liver Disease (EASL).|
Susanne Dam Poulsen
|Susanne Dam Poulsen (given name Susanne Dam Nielsen), Copenhagen, Denmark.
Susanne Dam Poulsen is professor of infectious diseases at Department of Infectious Diseases, University of Copenhagen Rigshospitalet. She has worked with HIV, inflammation, and immunology for 25 years, and the last decade she has worked with HIV-related comorbidities. She now leads a research team that studies HIV comorbidities, and she is the PI of the Copenhagen Comorbidity in HIV (COCOMO) study.
|Prof John Dillon is Professor of Hepatology and Gastroenterology and a principle investigator, in the Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, based at Ninewells hospital, Dundee. He is also an Honorary Consultant with NHS Tayside, leading a busy general hepatology service and a research group. He graduated in medicine from St Georges Hospital Medical School, University of London, and subsequently gained his MD based on research performed in the University of Edinburgh while a lecturer in Gastroenterology and Hepatology.
His award winning research interests included; new pathways of care for patients with abnormal LFTs, for people infected with HCV, new therapies for HCV infection, as well as novel diagnostics and treatments for NAFLD. His research activities stretch from the bench to the bedside and out into the community. He has published over 150 peer reviewed original research papers. He chairs the Scottish HCV Action Plan Clinical Leads Group, is a member of the Scottish Government’s Ministerial advisory board for Blood Borne viruses and sexual health and is the previous President of the Scottish Society of Gastroenterology. He previously led the development group of the UK consensus guidelines for HCV and has chaired the Hepatitis C SIGN guideline development group. He Chaired the SHAAP group that produced the recent “Alcohol-related liver disease: guidance for good practice” documents. He has delivered over 200 international lectures on liver disease.
|Lucy Dorrell hold dual appointments as a Professor of Immunology at the Nuffield Department of Medicine, University of Oxford and Head of Translational Medicine – Infectious Diseases at Immunocore, a UK/US biotech. She has worked in the field of HIV as a researcher and physician for the past 25 years, focusing on the development of immunotherapies for HIV and other sexually transmitted infections.|
|Dr. Estes obtained his Ph.D. in Immunology and HIV Pathogenesis in 2003 from Brigham Young University working in the laboratory of Dr. Gregory Burton. From 2003 to 2007, he was a postdoctoral fellow in the laboratory of Dr. Ashley Haase in the Department of Microbiology at the University of Minnesota focusing on the in vivo immunopathology of HIV/SIV infections. Following his postdoctoral training, Dr. Estes joined the AIDS and Cancer Virus Program at the Frederick National Laboratory for Cancer Research led by Dr. Jeff Lifson, and was a Senior Principal Investigator of the Retroviral Immunopathology Section and Head of the Tissue Analysis Core. Dr. Estes was appointed an Adjunct Professor in the School of Health and Biomedical Sciences in the College of Science, Engineering and Health at RMIT University in Melbourne, Australia in 2017. Later in 2017, Dr. Estes accepted a dual appointment as Professor within the Vaccine and Gene Therapy Institute (VGTI) and Chief of the Division of Pathobiology & Immunology at the Oregon National Primate Research Center (ONPRC) at Oregon Health & Science University (OHSU). The central focus of Dr. Estes’s research seeks to understand how HIV/SIV-driven immune response dysregulation leads to tissue pathology, disease progression, and viral persistence with the goal to develop and test effective therapeutic strategies that prevent disease, restore immune function and impact viral reservoir persistence.|
|John is a MRC Senior Clinical Fellow and Professor of Infectious Diseases at the University of Oxford. He is the scientific lead and co-founder of ‘CHERUB’, an NIHR-supported UK collaboration dedicated to finding a cure for HIV infection. He also works as an Honorary Consultant Physician in HIV and Infectious Diseases. The aim of his research is to understand better the reservoir of ‘latent’ HIV infection in treated individuals, and to pursue strategies for curing HIV infection with a specific interest in primary HIV infection.|
|Jan Gerstoft is professor of clinical virology at the University of Copenhagen, Denmark. He works at the department of infectious diseases at Rigshospitalet where he is heading the outpatient clinic that primarily takes care of HIV and hepatitis patients. His research has mainly been focused on HIV, since he described the first European AIDS patients in 1981. His research has involved clinical trials of antiviral agents, resistance and cohort studies of co-morbidities. The research has been published in more than 400 papers often in high impact journals.|
|Marianne Jansson, Associate Professor in Virology, at Department of Laboratory Medicine, Lund University, has worked within the field of HIV research for the past 25 years. She today heads a research team which focus is studies on pathogenesis, immune response and host cell interactions in HIV-1 and HIV-2 infections, as well as in tuberculosis coinfections.|
|Senior consultant at the Department of Infectious Diseases, Skane University Hospital, Malmö.
Area of research: Hepatitis C in people who inject drugs. Have conducted clinical trials on hepatitis C treatment in the OST (opiate substitution treatment) and NEP (needle exchange program) setting.
Terese L Katzenstein
|Terese L Katzenstein is chief physician at the Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet. Terese Katzenstein has been involved in HIV treatment and research for more than 20 years. Terese Katzenstein has a special interest in women living with HIV and their children. Both her PhD and MDSc theses were based on studies within the field of clinical virology. Dr. Katzenstein has authored/co-authored more than 140 publications, primarily on HIV related issues. Current research activities includes studies on bone health and treatment optimization and monitoring in Tanzania.|
|Martin Kåberg MD, PhD is a Senior Consultant in Psychiatry/Addiction Medicine and Infectious Diseases and the Medical Supervisor for the Stockholm Needle Exchange Programs at Stockholm Centre for Dependency Disorders.|
|Anne-Geneviève Marcelin is Professor of Medicine at Sorbonne Université in Paris, France and clinical virologist at the Pitié-Salpêtrière Hospital. She’s head of a research team (Inserm UMR 1136) dedicated to Therapeutic strategies for HIV infection and associated viral diseases.
Pr Anne-Geneviève Marcelin research interests include HIV mechanisms of resistance to antiretrovirals, new therapy strategies for HIV treatment and new antiretroviral agents. She serves as a member of Agence Nationale de Recherches sur le SIDA et les hepatites virales (ANRS), in the French AC43 resistance group (www.hivfrenchresistance.org) and is chair of the ANRS Next generation sequencing network.
She’s member of the WHO Steering Group that provides high level guidance and supports in developing and implementing WHO global HIV drug resistance prevention, surveillance and response strategy and is co-chair of the WHO Working Group 3, on Research and Innovation.
|Beatriz Mothe, MD, PhD works as a physician and researcher at IrsiCaixa AIDS Research Institute in Barcelona, Spain since 2007, an institution that works to advance clinical research and translate results into patient’s care. During her PhD she focused her research on the study of immunological, virological and genetic mechanisms that determine control of HIV infection and that could be incorporated into the rational design of novel therapeutic vaccine candidates She has actively participated in the design (inventorship) and pre-clinical testing of a novel HIV T-cell immunogen (named HTI that is designed to redirect CTL responses towards protective and conserved HIV targets able to control viral replication, which has been licensed to Aelix Therapeutics, and is already in clinical human testing. After research stays at Ragon Institute in Boston (former PARC) and NCI-Frederick, she performed a postdoctoral research fellow program associated with the group of Host Genetics and Cellular Immunology led by Dr. Brander. She keeps a part-time activity in the Infectious Disease Department of the Hospital Universitari Germans Trias I Pujol where she focus her activity on the identification and early treatment of acute/recent HIV infection and the monitoring of patients with a profile of HIV controllers as models for a functional cure. As a clinical researcher, she is the principal investigator of the Inmunology, Vaccines and Pharmacology group where she coordinates the development of clinical trials and their immunomonitoring in the areas of therapeutic vaccines and eradication strategies, reflecting her translational profile. She is an associate professor in the Department of AIDS and Associated Diseases at the University of Vic and Central Catalonia (UVic-UCC) since 2014.|
|Chloe Orkin is a Professor of HIV Medicine at Queen Mary University of London and Consultant Physician at the Royal London Hospital. She is Chair of the British HIV Association and Vice President of the Medical Women's Federation (UK). She runs a busy HIV & HIV/ HCV clinical trials unit. Her specialist interests are: antiretroviral therapy and blood-borne virus testing.|
|Jannick Snel-Prentø, PhD is employed as Associate Professor at Department of Immunology and Microbiology at University of Copenhagen (UCPH), Denmark. His group in the Copenhagen Hepatitis C Program (CO-HEP), which is a joint venture between Hvidovre Hospital and UCPH, focuses on hepatitis C virus (HCV) research. This includes understanding immune evasion strategies of HCV with a focus on entry and neutralizing antibodies including their relevance in rational vaccine design against this important viral pathogen.|
|Ronald Swanstrom is Professor of Biochemistry and Biophysics and Director of the UNC Center For AIDS Research, University of North Carolina at Chapel Hill, USA. He studies HIV-1 evolution and pathogenesis, especially as it pertains to viral entry and cell tropism. Other interests include the viral protease and protease inhibitors, and viral RNA splicing. A recent focus has been the study of when HIV-1 enters the long-lived viral reservoir that persists during suppressive antiviral therapy.|
|Johannes Vermehren is Associate Professor of Medicine at the University Hospital in Frankfurt, Germany. He trained at the medical schools in Freiburg and Hamburg, graduating in medicine in 2006. He served as a postdoctoral fellow specializing in Internal Medicine, Gastroenterology and Hepatology at the Saarland University Hospital in Homburg/Saar, Germany under the supervision of Prof. Stefan Zeuzem. Later he continued his training at the University Hospital Frankfurt. In 2011 he was a research scholar at the Institute of Clinical Pharmacology at the University Hospital Frankfurt. In 2014 he became Assistant Professor of Medicine. For more than 10 years, Dr. Vermehren has worked on basic and clinical aspects of hepatitis virus infections, and has participated in numerous national and international Phase I–III studies in chronic viral hepatitis. Dr. Vermehren has authored numerous publications and several book chapters on basic research and clinical aspects of chronic liver diseases. His main research interests include molecular HCV RNA assays, resistance to direct antivirals and methods of non-invasive liver fibrosis assessment.|
|Sharon Walmsley, MD, is the Director of the Immunodeficiency Clinic and HIV Clinical Research at Toronto General Hospital, University Health Network and a Professor, University of Toronto Department of Medicine. She is a Senior Scientist at the Toronto General Hospital Research Institute and the Co- Chair of the CIHR- Canadian HIV Trials Network. She is actively involved in the design and conduct of many clinical trials, including trials in HIV therapy; prophylaxis and treatment of opportunistic infections, and management of the complications of treatment. Current research interests involve the interaction between HIV and herpes virus co-infection. She also has a strong interest in HIV in women, and is a co-investigator of the Canadian Women's HIV Study group which is currently evaluating the HPV vaccine in HIV infected women and girls. She holds numerous peer-reviewed publications and research awards related to clinical trials in HIV. She is the recipient of a Chair in HIV Clinical Management and Aging from the Ontario HIV Treatment Network. In June 2017, she was appointed as a Member of the Order of Canada for my contributions in HIV Research.|
|Ola Weiland has a present position as senior professor in Infectious Diseases at Karolinska Institutet at the Department of Medicine, Karolinska Institutet, and a senior consultancy at Karolinska University Hospital Huddinge, Stockholm, Sweden. Professor Weiland has received his medical degree from Karolinska Institute in 1972 and achieved board certification as a Specialist in Infectious Diseases in 1977. His research on hepatitis A, B and non-A, non-B virus gained him a PhD at the Karolinska Institute in 1981. Professor Weiland is a member of the European and American Association for Study of the Liver, the Infectious Disease Society of America, and the Swedish Societies for Medicine, Infectious Diseases, and Tropical Medicine. He is also president of the Society of the Scandinavian Journal of Infectious Diseases and is on the board of the Scandinavian Journal of Gastroenterology. He has published over 250 original articles, in addition to 40 reviews or book chapters. His main research interests covers the mechanisms of action, immunological response to, clinical development, and evaluation of antiviral therapy for chronic hepatitis B and C.|
|Anne Øvrehus is a Clinical Associate Professor in Infectious Diseases at University of Southern Denmark and a Consultant at the Department of Infectious Diseases , Odense University Hospital Denmark. Her research interests includes both epidemiological and clinical aspects of chronic viral hepatitis in people who use drugs. Dr. Øvrehus is the primary investigator of several ongoing studies and trials on hepatitis C in people who use drugs and is co-chair of a regional elimination program in the Region of Southern Denmark. As a clinician she provides hepatitis care both in a hospital and a community setting. She has a longstanding interest in Medical Education and serves in INHSU Educational board.|